PaxMedica stock soars 110% on FDA update for lead drug PAX-101Shares of PaxMedica (NASDAQ:PXMD) shot up 110% in early trading after the biotech company said that it now expects to file its New Drug Application for PAX-101 in the second half of 2024.
The biotech company said it received constructive feedback at a recent type-B meeting with the FDA that will he